An Italian registry study of individuals with achondroplasia or hypochondroplasia (NCT05328050) and an investigator-initiated, open-label, single-arm study (NCT04219007) of the effects of vosoritide in patients with various skeletal dysplasias, including hypochondroplasia, ACAN variants, SHOX gene defects, Noonan syndrome, and neurofibromatosis type 1, are expected to provide preliminary information about the effectiveness of vosoritide for treatment of these other skeletal disorders. This evidence concerns the gene ACAN and hypochondroplasia.